Sandbox Reserved 1490

From Proteopedia

Jump to: navigation, search
This Sandbox is Reserved from 06/12/2018, through 30/06/2019 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1480 through Sandbox Reserved 1543.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Crystal structure of cytoplasmic kinase domain of Tie2 in complex with decipera compound DP1919

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, Shibuya M, Takakura N, Koh GY, Mochizuki N. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol. 2008 May;10(5):513-26. doi: 10.1038/ncb1714. Epub 2008 Apr 20. PMID:18425120 doi:10.1038/ncb1714
  2. 2.0 2.1 Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 2009 Apr;29(8):2011-22. doi: 10.1128/MCB.01472-08. Epub 2009 Feb, 17. PMID:19223473 doi:10.1128/MCB.01472-08
  3. 3.0 3.1 Murray BW, Padrique ES, Pinko C, McTigue MA. Mechanistic effects of autophosphorylation on receptor tyrosine kinase catalysis: enzymatic characterization of Tie2 and phospho-Tie2. Biochemistry. 2001 Aug 28;40(34):10243-53. PMID:11513602
  4. 4.0 4.1 4.2 Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS, Dumont DJ. A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Mol Cell Biol. 2003 Apr;23(8):2658-68. PMID:12665569
  5. 5.0 5.1 5.2 Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996 Dec 27;87(7):1181-90. PMID:8980225
  6. 6.0 6.1 Kangas J, Natynki M, Eklund L. Development of Molecular Therapies for Venous Malformations. Basic Clin Pharmacol Toxicol. 2018 Sep;123 Suppl 5:6-19. doi: 10.1111/bcpt.13027., Epub 2018 May 29. PMID:29668117 doi:http://dx.doi.org/10.1111/bcpt.13027
  7. 7.0 7.1 7.2 Boscolo E, Limaye N, Huang L, Kang KT, Soblet J, Uebelhoer M, Mendola A, Natynki M, Seront E, Dupont S, Hammer J, Legrand C, Brugnara C, Eklund L, Vikkula M, Bischoff J, Boon LM. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest. 2015 Sep;125(9):3491-504. doi: 10.1172/JCI76004. Epub 2015 Aug 10. PMID:26258417 doi:http://dx.doi.org/10.1172/JCI76004
  8. Shlamkovich T, Aharon L, Koslawsky D, Einav Y, Papo N. Targeting the Tie2-alphavbeta3 integrin axis with bi-specific reagents for the inhibition of angiogenesis. BMC Biol. 2018 Aug 17;16(1):92. doi: 10.1186/s12915-018-0557-9. PMID:30119679 doi:http://dx.doi.org/10.1186/s12915-018-0557-9
Personal tools